Description  Claims  Cited references 

WO9962871A1   [0007] 
EP0903343B1   [0007] 
WO2012177956A1   [0007] 
US6099562A   [0287] 
US5886026A   [0287] 
US5304121A   [0287] 

Physiol Rev.   [0006] 
Diabetes   [0006] 
Biochemical Pharmacology   [0006] 
Nat. Med.   [0006] 
Am. J. Physiol. Endocrinol. Meta.   [0006] 
N. Engl. J. Med.   [0006] 
Periodic Table of the Elements, CAS version   [0067] 
Organic Chemistry   [0067] 
March's Advanced Organic Chemistry   [0067] 
Cancer Chemother. Rep.   [0130] 
Scientific Tables, Geigy Pharmaceuticals   [0130] 
The ACS Style Guide: A Manual for Authors and Editors   [0136] 
pharmaceutically acceptable salts in detail   [0268] 
Remington's Pharmaceutical Sciences   [0269] 
J. Org. Chem.   [0298] 
Bioorg. Med. Chem. Lett.   [0302] 
Liver-specific disruption of PPAR in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes   [0452] 
Glucose transport deficiency corrected by treatment with the oral anti-hyperglycemic agent Pioglitazone   [0453] 
Am. J. Physiol. Endocrinol. Metab.   [0455] 
Amer. J. Physiol   [0459]